Epidemiological and clinical factors associated with post-exertional malaise severity in patients with myalgic encephalomyelitis/chronic fatigue syndrome

Alaa Ghali1*, Paul Richa1, Carole Lacout1, Aline Gury1, Anne-Berengere Beucher1, Chadi Homedan2, Christian Lavigne1 and Geoffrey Urbanski1

Abstract

Background: Post-exertional malaise (PEM), the cardinal feature of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), occurs generally after exposure to a stressor. It is characterized by the worsening of ME/CFS symptoms and results in aggravating the course of the disease and the quality of life of patients. Due to its unpredictable onset, severity, and recovery time, identifying patients with higher risk for severe PEM would allow preventing or reducing its occurrence. We thus aimed at defining possible factors that could be associated with PEM severity.

Methods: Adult patients fulfilling ME international consensus criteria who attended the internal medicine department of University hospital Angers-France between October 2011 and December 2019 were included retrospectively. All patients were systematically hospitalized for an etiological workup and overall assessment. We reviewed their medical records for data related to the assessment: epidemiological data, fatigue features, clinical manifestations, and ME/CFS precipitants. PEM severity was appreciated by the Center for Disease Control self-reported questionnaire. The study population was classified into quartiles according to PEM severity scores. Analyses were performed with ordinal logistic regression to compare quartile groups.

Results: 197 patients were included. PEM severity was found to be positively associated with age at disease onset ≥32 years (OR 1.8 [95% CI 1.1–3.0] (p = 0.03)), recurrent infections during the course of the disease (OR 2.1 [95% CI 1.2–3.7] (p = 0.009)), and when ME/CFS was elicited by a gastrointestinal infectious precipitant (OR 5.7 [1.7–19.3] (p = 0.006)).

Conclusion: We identified some epidemiological and clinical features, which were positively associated with PEM severity in subsets of ME/CFS patients. This could help improving disease management and patients' quality of life.

Keywords: Myalgic encephalomyelitis/chronic fatigue syndrome, Post-exertional malaise, Age, Recurrent infections, Infectious precipitants

*Correspondence: alghali@chu-angers.fr
1 Department of Internal Medicine, University Hospital, 49000 Angers, France
Full list of author information is available at the end of the article

© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
associated with a variety of symptoms, especially unrefreshing sleep, cognitive difficulties, orthostatic intolerance, and pain. Nevertheless, the post-exertional malaise (PEM) is the cardinal feature of ME/CFS, and recent diagnostic criteria require its presence [2–4]. It helps to distinguish ME/CFS from idiopathic chronic fatigue [3], and other diseases with chronic fatigue such as multiple sclerosis [5], depression [6], and systemic lupus erythematosus [7]. PEM is not just generalized fatigue, but an abnormal worsening of a patient’s baseline symptoms after exposure to physical or cognitive stressors that were normally tolerated before disease onset [3, 4]. The type, intensity, and frequency of PEM symptoms are often unexpected and out of proportion to the type, intensity, frequency, and duration of the PEM stressor [4].

Several PEM stressors were reported, especially physical or cognitive exertion [8], emotional distress [9], infections [4, 10], exposure to chemicals [11], physical trauma, and sleep debt [4]. PEM onset is unpredictable since it may occur immediately after stressor or delayed by several hours or days. Similarly, PEM duration varies largely not only between patients but also within the same patient and over the course of the disease. This variation is probably at least partially dependent on the baseline state of individuals such as for instance the level of exertion involved several days before PEM onset or the presence of infection [9]. The pathophysiology of PEM is not yet well understood. However some studies showed that mitochondrial dysfunction may have a role in PEM nature [12, 13]. We recently reported that elevated blood lactate levels at rest in a subgroup of ME/CFS patients were associated with more severe PEM [14].

In the absence of ME/CFS treatment and given the fact that PEM was found to be significantly associated with disability [15] and predict a poorer outcome for patients [16], the prevention of its occurrence, or at least reducing its severity, is very important to prevent disease exacerbation. Our study aimed at identifying possible epidemiological and/or clinical factors that could be associated with PEM severity.

**Methods**

The study was approved by the ethics committee of the University hospital of Angers (2018/46) and was conducted in compliance with the Helsinki agreement.

We reviewed all medical records of patients attending the outpatient clinic of the internal medicine department of Angers University Hospital and diagnosed as having ME/CFS between October 1, 2011 and December 31, 2019. The diagnosis of ME/CFS was established by the same physician. We enrolled all patients aged ≥18 years who met the ME International Consensus Criteria (ME ICC) 2011 [3]. In accordance with these criteria, patients with an identifiable medical condition that could account for chronic fatigue, and those with primary psychiatric disorders or substance dependence were excluded. According to ME ICC, comorbidities such as fibromyalgia, irritable bowel syndrome (IBS), Hashimoto’s thyroiditis, and reactive depression did not constitute an exclusionary condition. Epidemiological data, fatigue features, ME/CFS precipitants, and comorbidities were collected for each patient. Patterns of symptom clusters according to the ME ICC criteria were carefully extracted [3].

Fatigue level was assessed by means of validated self-reported questionnaires; the fatigue scale (FS) [17] and the fatigue severity scale (FSS) [18]. The impact of fatigue on patient activities was assessed by the modified fatigue impact scale (MFIS) [19].

PEM severity over the past month was assessed by means of the PEM item from the standardized self-reported questionnaire of Center for Disease Control and Prevention Symptom Inventory (CDC SI) [20]. Perceived frequency of PEM was rated on a 4-point scale (1 = a little of the time, 2 = some of the time, 3 = most of the time, 4 = all of the time), and its intensity was measured on a 3-point scale (1 = mild, 2 = moderate, 3 = severe). The intensity score was converted into equidistant score (0 = symptom not reported, 1 = mild, 2.5 = moderate, 4 = severe). The frequency and intensity scores were then multiplied to create the PEM severity score ranging from 0 to 16.

In the absence of a validated threshold defining PEM severity, patients were grouped into quartiles (Q) according to PEM severity scores of the studied population: Q1 (mild PEM with scores ≤ 5); Q2 (moderate PEM with scores 7.5, 8, and 10); Q3 (severe PEM with score = 12), and Q4 (very severe PEM score = 16).

Qualitative data were expressed as an absolute number and percentage. Quantitative data were expressed as median and quartiles. The alpha risk was set at 5%. The odds ratio (OR) was presented with its 95% confidence interval (CI). Analyses were performed with ordinal logistic regression to compare the 4 quartile groups. All covariates of a domain were included in the first model for each analysis. We rejected models that did not satisfy validation conditions for ordinal regression: (i) model has to differ from the intercept based on the Chi²-square test on -2log-likelihood ratio (p value<0.05) and (ii) model has to validate the proportional odds assumption with no difference on the parallel lines test (p-value>0.05). The final model was created by removing variables one by one with a descending stepwise method and was the first one to validate both the test of parallel lines and the test on -2log-likelihood ratio. The analyses were performed using SPSS software v23.0 (IBM Corp).
Results
Among the 203 patients who were fulfilling inclusion criteria, we excluded 6 patients in whom data concerning PEM assessment were missing in their medical records, so 197 patients were included in the study. The whole population had a median age at disease onset of 32 [25–40] years, a median body mass index of 22.8 [20.0–25.9] kg/m², and a male to female ratio of 1:2.9. The median delay in diagnosis was 47 [22–102] months. Results of the current study showed that older age at disease onset, susceptibility to viral infections during the course of the disease, and GI infections prior to disease onset were independently associated with PEM severity. Results of the current study showed that older age at disease onset, susceptibility to viral infections during the course of the disease, and GI infections prior to disease onset were independently associated with PEM severity. The prevention of PEM occurrence or reducing its severity is thus one of the main goals of pacing strategies, which proved successful in ME/CFS management [21]. We thus attempted to determine whether there are factors that could be associated with PEM severity. Results of the current study showed that older age at disease onset, susceptibility to viral infections during the course of the disease, and GI infections prior to disease onset were independently associated with PEM severity.

In the study population, the median age of disease onset of 32 [5–40] years and the higher prevalence of women were comparable to that previously reported [4, 22]. The median time to diagnosis was 47 [22–102] months, which is consistent with the IOM report [4] that showed that time between the onset of symptoms and the diagnosis was longer than 5 years in about a third of patients.

Fatigue assessment showed high median levels of reported fatigue in the whole population with no significant difference between quartiles. This could be explained by the subjective nature of fatigue and the fact that current available fatigue scales would not accurately reflect fatigue severity in chronic fatigue patients [23]. PEM severity was assessed in all patients by the standardized CDC SI self-reported questionnaire [20], which is a reliable and valid instrument for assessing symptoms associated with CFS including PEM, and one of the two tools proposed by the IOM for PEM assessment [4]. CDC SI severity scores reflect both intensity and frequency of PEM and thus offer a means of answering the question of what is more serious: a substantial PEM that appears irregularly or less important PEM that occurs repeatedly. To date, there is still no validated threshold defining PEM severity, so we classified our population into quartiles according to PEM severity.

The first finding of our study is that older age at onset, ≥32 years, was positively associated with PEM severity. The best of our knowledge, the influence of age at ME/CFS onset on PEM severity was not reported before. Nevertheless, there are some evidences that age is linked to the course of the disease. In that respect, increasing age predicted worsening of symptoms with poor prognosis in patients with CFS [24, 25], and an age over 38 years at diagnosis was found to be a risk factor for persistent illness [26]. Jason et al. reported that CFS patients who were older had higher frequencies of symptoms and were more severely disabled [27]. By contrast, Wilson et al. showed that age did not predict outcome in CFS patients [28]. On the other hand, it is generally accepted that young people with ME/CFS have a more favorable prognosis and are more likely to improve and recover compared to adults [29, 30].

Age could therefore be an important element to consider in the management of ME/CFS patients, especially in terms of PEM severity. Subtyping ME/CFS patients according to age would allow identifying a group of patients with higher risk for severe PEM, and therefore needing better adherence to pacing approaches in order to avoid PEM occurrence and prevent exacerbation of the disease.

The second major finding in our study is that recurrent viral infections during the course of the disease were...
Table 1 Characteristics of patients according to post-exertional malaise severity quartiles

| Epidemiological data | Quartile 1 mild PEMa | Quartile 2 moderate PEM | Quartile 3 severe PEM | Quartile 4 very severe PEM |
|----------------------|----------------------|-------------------------|-----------------------|---------------------------|
| Patients, n (%)      | 23 (11.7)            | 74 (37.6)               | 73 (37.1)             | 27 (13.7)                 |
| Females, n (%)       | 17 (73.9)            | 58 (78.4)               | 50 (68.5)             | 21 (77.8)                 |
| Basal metabolic index, kg/m² | 23.7 [20.2–26.3] | 23.3 [20.3–25.9]         | 22.5 [19.6–25.9]      | 21.9 [20.1–24.6]           |
| Age at disease onset, years | 28 [21–38]     | 32 [25–41]              | 32 [27–39]            | 38 [31–41]                |
| Delay in diagnosis, months | 60 [25–108]  | 62 [29.6–120]            | 44 [21–95]            | 26 [17–54]                |
| Fatigue features     |                      |                         |                       |                           |
| Fatigue severity scale | 5.4 [5–6] (n = 18) | 5.5 [5.03–6.2] (n = 58) | 5.9 [5.15–6.5] (n = 59) | 5.9 [5.2–6.7] (n = 17) |
| Fatigue scale        | 24 [18–27.5] (n = 15) | 21 [18–25.5] (n = 59) | 25 [22–28] (n = 61) | 26 [22–28] (n = 21) |
| MFISb physical       | 29.5 [26.5–32] (n = 16) | 28 [24.3–31.8] (n = 58) | 31 [27–33] (n = 59) | 30 [26.5–33] (n = 22) |
| MFIS cognitive       | 24 [19–34] (n = 16) | 26 [19.2–30] (n = 58) | 31 [24.5–33.5] (n = 59) | 26 [22.3–30.6] (n = 22) |
| MFIS psychosocial    | 6 [5–7] (n = 16) | 5 [4–6] (n = 58) | 6 [5–8] (n = 59) | 6 [5–7] (n = 22) |
| Symptom clustersc, n (%) |                      |                         |                       |                           |
| Neurological impairments | 23 (100)           | 74 (100)                | 73 (100)              | 27 (100)                  |
| Neurocognitive impairments | 23 (100)           | 74 (100)                | 73 (100)              | 27 (100)                  |
| Difficulty processing information | 23 (100) | 68 (91.9)               | 70 (95.9)             | 27 (100)                  |
| Short-term memory loss | 16 (69.6)           | 62 (83.8)               | 66 (90.4)             | 24 (88.9)                 |
| Pain                 | 22 (95.7)           | 72 (97.3)               | 71 (97.3)             | 26 (96.3)                 |
| Headaches            | 16 (69.6)           | 53 (71.6)               | 56 (76.7)             | 21 (77.8)                 |
| Significant pain     | 19 (82.6)           | 64 (86.5)               | 68 (93.2)             | 26 (96.3)                 |
| Sleep disturbances   | 22 (95.7)           | 74 (100)                | 72 (98.6)             | 27 (100)                  |
| Disturbed sleep patterns | 21 (91.3)    | 65 (87.8)               | 64 (87.7)             | 22 (81.5)                 |
| Unrefreshed sleep    | 21 (91.3)           | 74 (100)                | 69 (94.5)             | 25 (92.6)                 |
| Neurosensory, perceptual and motor disturbances | 22 (95.7) | 73 (100) | 73 (100) | 27 (100) |
| Neurosensory and perceptual troubles | 20 (87) | 62 (83.8) | 69 (94.5) | 23 (85.2) |
| Motor disturbances   | 20 (87)             | 69 (93.2)               | 69 (94.5)             | 27 (100)                  |
| Immune, gastrointestinal, and genitourinary impairments | 21 (91.3) | 66 (89.2) | 71 (97.3) | 24 (88.9) |
| Flu-like symptoms    | 16 (69.6)           | 50 (67.6)               | 59 (80.8)             | 19 (70.4)                 |
| Susceptibility to viral infections | 3 (13) | 26 (35.1) | 31 (42.5) | 12 (44.4) |
| Gastrointestinal impairments | 17 (73.9) | 63 (85.1) | 60 (82.2) | 22 (81.5) |
| Genitourinary impairments | 2 (8.7) | 28 (37.8) | 29 (39.7) | 7 (25.9) |
| Sensitivities to food, medications, odors, or chemicals | 2 (8.7) | 6 (8.1) | 4 (5.5) | 35 (11.1) |
| Energy production/transportation impairments | 22 (95.7) | 74 (100) | 72 (98.6) | 27 (100) |
| Cardiovascular manifestations | 19 (82.6) | 72 (97.3) | 65 (89) | 27 (100) |
| Respiratory manifestations | 9 (39.1) | 36 (48.6) | 38 (52.1) | 19 (70.4) |
| Loss of thermostatic instability | 18 (78.3) | 65 (87.8) | 61 (83.6) | 26 (96.3) |
| Intolerance of extremes of temperatures | 13 (56.5) | 61 (82.4) | 42 (57.5) | 21 (77.8) |

Categorical data were expressed as absolute number and percentage
Continuous data were expressed as median and quartiles

a Post-exertional malaise
b Modified fatigue impact scale
cc ME International Consensus Criteria [3]
positively associated with PEM severity (OR 2.1 [95% CI 1.2–3.7] (p = 0.009)).

Although the exact ME/CFS pathogenesis is still unknown, there is a growing body of evidence that immune dysfunction elicited by the initial infectious precipitant is one of the main mechanisms involved in ME/CFS [31, 32]. A number of studies reported reduced NK activity making these cells unable to clear viral and other microbial infections, which could explain the susceptibility of these patients to recurrent viral infections [33, 34]. High levels of pro-inflammatory cytokines and a shift towards Th2 response were also reported and seemed to be responsible for some of ME/CFS manifestations such as fatigue and flu-like symptoms [35]. Other factors in ME/CFS patients, such as sleep disturbances, mood changes, and psychological stress can also impact the immune system, thus inducing and/or maintaining immune function abnormalities that contribute to a susceptibility to recurrent, severe, or prolonged viral infections [36]. Faulkner et al. reported frequent recurrence of upper respiratory tract infections in CFS patients compared to healthy controls, and always preceded by high psychological stress and negative mood [37]. Infections were reported to be one of the PEM stressors [10, 12], therefore recurrent infections will result in more frequent and severe PEM and worsening of ME/CFS baseline symptoms. This in turn will perpetuate the immune dysfunction leading to increasing susceptibility to viral infections and symptom severity. It is very likely that the more the patient with ME/CFS has repeated viral infections, the higher the frequency and intensity of his PEM. The 2-way link between recurrent viral infections and PEM severity is illustrated in Fig. 1. Nevertheless, immune function abnormalities are not encountered in all ME/CFS patients and only a subset of patients experience immune/inflammatory-related symptoms. This

| Table 2 Epidemiological and clinical patients’ characteristics associated with post-exertional malaise severity in an adjusted model |
|-------------------------------------------------|----------|----------|
| Post-exertional malaise severity quartiles       | p-value  | OR [95% CI]|a |
| Quartile 1 Reference                             |          |          |
| Quartile 2                                       | 0.25     |          |
| Quartile 3                                       | 0.03     |          |
| Quartile 4                                       | 0.002    |          |
| Variables                                       |          |          |
| Age at onsetb                                  | 0.03     | 1.8 [1.1–3.0] |
| Sex (female)                                  | 0.30     | 0.7 [0.4–1.3] |
| Neurosensory, perceptual and motor disturbances | 0.20     | 6.5 [0.4–108.6] |
| Sleep disturbances                             | 0.25     | 4.7 [0.3–65.5] |
| Susceptibility to viral infections              | 0.009    | 2.1 [1.2–3.7] |
| Respiratory manifestations                     | 0.06     | 1.7 [1.0–2.9] |
| Loss of thermostatic instability                | 0.24     | 1.6 [0.7–3.7] |

Multivariate analysis was performed with ordinal regression. All variables including age at disease onset, sex, and symptom clusters of ME ICC criteria [3] were included in the initial model. The initial model did not meet the validation conditions: the model significantly differed from the intercept (p = 0.01) and failed to validate the proportional odds assumption (p = 0.001). The final model was created by removing the variables one by one with a descending stepwise method until validation of both the parallel lines test (p = 0.242) and the test on -2log-likelihood ratio from the intercept (p = 0.009)

a Odds Ratio with 95% Confidence interval

b Age as a categorical variable with a cut-off ≥ the median age of the study population (32 years)

| Table 3 Distribution of ME/CFS precipitants according to post-exertional malaise severity quartiles |
|-------------------------------------------------|----------|----------|
| Patients, n (%)                                  | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 |
| ME/CFS precipitants                             | 23 (11.7)  | 74 (37.6)  | 73 (37.1)  | 27 (13.7)  |
| Identified, n (%)                               | 18 (78.3)  | 46 (62.2)  | 56 (76.6)  | 19 (70.4)  |
| Non-infectious, n (%)                           | 4 (17.4)   | 17 (23)    | 17 (23)    | 4 (14.8)   |
| Infectious, n (%)                               | 14 (60.9)  | 29 (39.2)  | 39 (53.4)  | 15 (55.6)  |
| Influenza-like illness                          | 10 (43.5)  | 13 (17.6)  | 21 (28.8)  | 7 (25.9)   |
| Respiratory                                    | 0 (0.0)    | 9 (12.2)   | 6 (8.2)    | 3 (11.1)   |
| Gastrointestinal                               | 0 (0.0)    | 3 (4.1)    | 3 (4.1)    | 5 (18.5)   |
| Urinary                                        | 0 (0.0)    | 1 (1.4)    | 1 (1.4)    | 0 (0.0)    |

| Table 4 ME/CFS precipitants associated with post-exertional malaise severity in an adjusted model |
|-------------------------------------------------|----------|----------|
| Post-exertional malaise severity quartiles      | p-value  | OR [95% CI]|a |
| Quartile 1 Reference                            |          |          |
| Quartile 2                                       | <0.0001  |          |
| Quartile 3                                       | 0.006    |          |
| Quartile 4                                       | <0.0001  |          |
| Variables                                       |          |          |
| Non-infectious precipitants                     | 0.51     | 1.3 [0.6–2.6] |
| Infectious precipitants                         |          |          |
| Influenza-like illness                          | 0.30     | 1.4 [0.7–2.8] |
| Gastrointestinal                               | 0.006    | 5.7 [1.7–19.3] |
| Urinary                                        | 0.55     | 2.2 [0.2–30.2] |
| Respiratory                                    | 0.44     | 1.5 [0.6–3.8] |

Multivariate analysis was performed with ordinal regression. All listed precipitants were included in the initial model and adjusted for previously identified variables (age at disease onset and susceptibility to viral infections). The initial model met the validation conditions: the model differed from the intercept (p = 0.01) and validated the proportional odds assumption (p = 0.23). Age at disease onset (p = 0.03) and susceptibility to viral infections (p = 0.02) remained associated with PEM severity quartiles

a Odds Ratio with 95% Confidence interval
provides supplementary evidence for the non-homogeneity of the ME/CFS population [34]. The identification of this subset of patients would aid the individualization of patient’s care and allow researchers to find a targeted treatment. Measures against infections, especially viral, and good personal hygiene are highly required among ME/CFS patients with recurrent viral infections, who need to give much more attention to avoiding infections. The association of recurrent viral infections with severe PEM led us to examine ME/CFS precipitants in our study population, especially infectious precipitants. Amongst the different ME/CFS precipitants, only GI precipitants were associated with more severe PEM (OR 5.7 [1.7–19.3] (p = 0.006)), as shown by an adjusted analysis. A recent study including a large cohort of patients observed an association between all types of GI infections and CFS [38]. Giardia lamblia gastritis [39], gastroenteritis [2], chronic intestinal candidiasis [40], and enteroviruses [41], especially coxsackie viruses [42], were reported to have a causative role in triggering CFS. Mucosal barrier dysfunction and an increase in gut permeability were reported in ME/CFS resulting in bacterial translocation and consequently a rise in serum endotoxin concentrations, which leads to triggering the immune response [43]. Intestinal microbiota is also found to be altered in ME/CFS patients and thus could contribute to ME/CFS symptoms via increased LPS translocation from gram-negative enterobacteria [44]. GI manifestations are common in ME/CFS and many patients report a previous diagnosis of IBS [45]. Interestingly, both ME/CFS and IBS are sharing many similarities. They may follow bacterial and parasite-induced gastroenteritis, as well as viral disease [39], and gut dysbiosis was reported in both conditions [12]. ME/CFS patients with comorbid IBS may constitute a distinct ME/CFS subgroup, characterized by more severe fatigue and GI symptoms [44]. Dysbiosis could thus trigger autoimmunity, which in turn might be responsible for mitochondrial dysfunction identified as having a role not only in PEM pathophysiology [12, 13], but also in terms of PEM severity as we have recently demonstrated [14]. Consequently, ME/CFS-related GI anomalies could explain increasing PEM severity observed in patients in whom the disease onset was preceded by the occurrence of GI infection.
Limitations and strengths
The statistically significant association observed between GI infectious precipitants and PEM severity must be interpreted with caution due to the small number of patients in whom the ME/CFS was preceded by GI infectious event. The multivariate analysis of factors associated with PEM severity included variables that were probably statistically underpowered (neurosensory, perceptual and motor disturbances, and sleep disturbances) and produced wide confidence interval. PEM assessment could be biased by the subjectivity of the used instrument and it would be better to support this assessment with an objective evaluation. At present, the only available objective instrument is the 2-day cardiopulmonary exercise test (CPET) that objectively demonstrates the loss of function and lack of recovery that occurs following exertion. However, the CPET carries substantial risk for patients as it may worsen their condition by triggering PEM. In addition, its systematic use in the research field is limited because of cost, expertise, and the level of severity of some participants [46]. Another source of weakness was the retrospective character of data collection and the lack of information concerning the mode of onset of the disease.

On the other hand, we would like to highlight the sizeable number of the study population and the fact that all patients were examined and diagnosed by the same physician, and underwent a same standardized procedure in terms of PEM and fatigue assessments. Clinical manifestations were studied on the basis of symptom patterns according to the ME ICC criteria [3]. It is also of interest to note that the statistical method was planned a priori and considered all variables without any selection.

Conclusion
Given the non-homogeneity of the ME/CFS population, and knowing that PEM is associated with disability and poorer outcome, we attempted to identify patients with higher risk for severe PEM on epidemiological and clinical features. To the best of our knowledge, our study is the first to identify factors that may influence PEM severity in ME/CFS patients.

We observed more severe PEM in older patients at disease onset, and among those who were suffering from recurrent infections during their disease course. More severe PEM was also observed in patients in whom ME/CFS onset was preceded by GI infectious precipitants.

Accordingly, this will allow adapting and individualizing the disease management, especially in the absence of curative treatment. Hence older patients should be advised to adhere more strictly to pacing strategies, and specific measures against infections together with pacing should be recommended for those who display recurrent and/or persistent infections. The aim is to prevent PEM occurrence, or at least reducing its severity, to help improving disease course and patients’ quality of life.

Acknowledgements
The authors would like to thank Maria Ghali, MD, department of general medicine, faculty of medicine, Angers for her aid in the collection and administration of data.

Authors’ contributions
AG contributed to the concept and design, to the acquisition of data, to the interpretation of the data, and to the critical writing, revised the intellectual content and approved the final version of the manuscript. PR, CLac, AGu, AB, B, CH, and CL contributed to the interpretation of data, revised the intellectual content and approved the final version of the manuscript. GU contributed to the concept and design, to the analysis and the interpretation of data and to the critical writing, revised the intellectual content and approved the final version of the manuscript. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Internal Medicine, University Hospital, 49000 Angers, France.
2 Department of Biochemistry and Genetics, University Hospital, 49000 Angers, France.

Received: 14 April 2020   Accepted: 15 June 2020

Published online: 22 June 2020

References
1. Prins JB, van der Meer JWMM, Bleijenberg G. Chronic Fatigue Syndr. Lancet. 2006;367:346–55.
2. Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner AM, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. J Chronic Fatigue Sy드n. 2003;11:7–115.
3. Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchel T, et al: Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med. 2011;270:327–38.
4… Committee on the Diagnostic Criteria for Myalgic Encephalopathy/ Chronic Fatigue Syndrome, Board on the Health of Select Populations, Institute of Medicine. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: redefining an illness. Washington (DC): National Academies Press (US), 2015. https://doi.org/10.17226/19012.
5. Morris G, Maes M. Myalgic encephalopathy/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics. BMC Med. 2013;11:205.
6. Hawk C, Jason LA, Torres-Harding S. Differential diagnosis of chronic fatigue syndrome and major depressive disorder. Int J Behav Med. 2006;13:244–51.
7. Jason AL, Zinn ML, Zinn AM. Myalgic encephalomyelitis: symptoms and biomarkers. Curr Neuropsychopharmacol. 2015;13:701–34.
8. Keech A, Sandler CX, Vollmer-Conna U, Cvejic E, Lloyd AR, Barry BK. Capturing the post-exertional exacerbation of fatigue following physical and cognitive challenge in patients with chronic fatigue syndrome. J Psychosom Res. 2015;79:337–49.

9. Chu U, Valenza JJ, Garvert DW, Montoya JG. Deconstructing post-exertional malaise in myalgic encephalomyelitis/chronic fatigue syndrome: a patient-centered, cross-sectional survey. PLoS One. 2018. https://doi.org/10.1371/journal.pone.0197811.

10. Holtzman C, Bhatia S, Cotter J, Jason L. Assessment of Post-Exertional Malaise (PEM) in Patients with Myalgic Encephalomyelitis (ME) and Chronic Fatigue Syndrome (CFS): a Patient-Driven Survey. Diagnostics. 2019;9:26.

11. Racciati D, Vecchiet J, Ceccomancini A, Ricci F, Pizzigallo E. Chronic fatigue syndrome following a toxic exposure. Sci Total Environ. 2001;270:27–31.

12. Blomberg J, Gottfried C-G, Elfvström A, Ritwan M, Rosén A. Infection elicits autoimmunity and myalgic encephalomyelitis/chronic fatigue syndrome: an explanatory model. Front Immunol. 2018. https://doi.org/10.3389/fimmu.2018.00229.

13. Myhlf S, Booth NE, McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med. 2009;2:1–16.

14. Ghali A, Lacout C, Ghali M, Gury A, Beucher A-B, Lozach P, et al. Elevated blood lactate in resting conditions correlate with post-exertional malaise severity in patients with Myalgic encephalomyelitis/Chronic fatigue syndrome. Sci Rep. 2019;9:18817. https://doi.org/10.1038/s41598-019-55473-4.

15. Nyland M, Naess H, Birkeland JS, Nyland H. Longitudinal follow-up of employment status in patients with chronic fatigue syndrome after mononucleosis. BMJ Open. 2014;4:e005798.

16. Taylor RR, Jason LA, Curie CJ. Prognosis of chronic fatigue in a community-based sample. Psychosom Med. 2002;64:319–27.

17. Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, et al. The Lupp LF, LaRocca NG, Muir-Nash J, Steinberg AD. Fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121–3.

18. Larson RD. Psychometric properties of the modified fatigue impact scale. Int J MS Care. 2013;15:15–20.

19. Wagner D, Nisenbaum R, Heim C, Jones JF, Unger ER, Reeves WC. Psychometric properties of the CDC Symptom Inventory for assessment of Chronic Fatigue Syndrome. Popul Health Metrics. 2005;3:8. https://doi.org/10.1186/1478-7954-3-8.

20. Geraghty K, Hann M, Kurten S. Myalgic encephalomyelitis/chronic fatigue syndrome patients' reports of symptom changes following cognitive behavioural therapy, graded exercise therapy and pacing treatments: analysis of a primary survey compared with secondary surveys. J Health Psychol. 2019;4:1318–33. https://doi.org/10.1177/1359105317726152.

21. Bakken IJ, Tveit K, Gunnels T, Ghaderi S, Stoltenberg C, Trogstad L, et al. Two age peaks in the incidence of chronic fatigue syndrome/myalgic encephalomyelitis: a population-based registry study from Norway 2008–2012. BMC Med. 2014;12:167.

22. Jason L, Evans JM, Brown M, Porter N, Brown A, Hurnell J, et al. Fatigue scales and chronic fatigue syndrome: issues of sensitivity and specificity. Disabil Stud Q. 2011;31:1375.

23. Joyce J. The prognosis of chronic fatigue and chronic fatigue syndrome: a systematic review. QJM. 1997;90:223–33.

24. Bombardier CH, Buchwald D. Outcome and Prognosis of patients with chronic fatigue vs chronic fatigue syndrome. Arch Intern Med. 1995;155:2105–10.

25. Clark MR, Katon W, Russo J, Kith P, Sintay M, Buchwald D. Chronic fatigue: risk factors for symptom persistence in a 2 1/2-year follow-up study. Am J Med. 1995;98:187–95.

26. Jason LA, Taylor RR, Kennedy CL, Jordan K, Song S, Johnson DE, et al. Chronic fatigue syndrome: sociodemographic subtypes in a community-based sample. Eval Health Prof. 2000;23:243–63.

27. Wilson A, Hickie I, Lloyd A, Hadzi-Pavlovic D, Boughton C, Dwyer J, et al. Longitudinal study of outcome of chronic fatigue syndrome. BMJ. 1994;308:756–9.

28. Rowe PC, Underhill RA, Friedman KJ, Gurvitt A, Medow MS, Schwartz MS, et al. Myalgic encephalomyelitis/chronic fatigue syndrome diagnosis and management in young people: a primer. Front Pediatr. 2017;5:121. https://doi.org/10.3389/fped.2017.00121.

29. Crawley E. Pediatric chronic fatigue syndrome: current perspectives. Pediatr Health Med Ther. 2018;9:27–33.

30. Glaser R, Kiecolt-Glaser JK. Stress-associated immune modulation: relevance to viral infections and chronic fatigue syndrome. Am J Med. 1998;105:355–425.

31. Lorusso L, Mikhailova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G. Immunological aspects of chronic fatigue syndrome. Autoimmunity Rev. 2009;8:287–91.

32. Brenu EW, van Driel ML, Staines DR, Ashton KJ, Hardcastle SL, Keane J, et al. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med. 2012;10:888. https://doi.org/10.1186/1479-5876-10-888.

33. Johnston S, Brenu EW, Staines D, Marshall-Gradiskis S. The prevalence of chronic fatigue syndrome/myalgic encephalomyelitis: a meta-analysis. Clin Epidemiol. 2013;5:105–10.

34. Broderick G, Fuite J, Kretz A, Vernon SD, Klimas N, Fletcher MA. A formal analysis of cytokine networks in chronic fatigue syndrome: Brain Behav Immun. 2010;24:1209–17.

35. Bansal AS, Bradley AS, Bishop KN, Kiani-Allkhan S, Ford B. Chronic fatigue syndrome, the immune system and viral infection. Brain Behav Immun. 2012;26:24–31.

36. Faulkner S, Smith A. A longitudinal study of the relationship between psychological distress and recurrence of upper respiratory tract infections in chronic fatigue syndrome. Br J Health Psychol. 2008;13:177–86.

37. Donnachie E, Schneider M, Erck P. Incidence of irritable bowel syndrome and chronic fatigue following Gi infection: a population-level study using routinely collected claims data. Gut. 2018;67:1078–86.

38. Hanevik K, Wensaas K-A, Rortveit G, Eide GE, March K, Langeland N. Irritable bowel syndrome and chronic fatigue 6 years after giardia infection: a controlled prospective cohort study. Clin Infect Dis. 2014;59:1394–400.

39. Carter RE. Chronic intestinal candidiasis as a possible etiological factor in the chronic fatigue syndrome. Med Hypotheses. 1995;44:507–15.

40. Chia JKS. The role of enterovirus in chronic fatigue syndrome. J Clin Pathol. 2005;58:1126–32.

41. Gow JW, Behan WM, Clements GB, Woodall C, Riding M, Behan PO. Enteroviral RNA sequences detected by polymerase chain reaction in muscle of patients with postviral fatigue syndrome. BMJ. 1991;302:692–6.

42. Maes M, Mihaylova I, Leunis J-C. Increased serum IgA and IgM against LPS of enterobacteria in chronic fatigue syndrome (CFS): indication for the involvement of gram-negative enterobacteria in the etiology of CFS and for the presence of an increased gut–intestinal permeability. J Affect Disord. 2007;99:237–40.

43. Lorusso L, Mikhailova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G. Immunological aspects of chronic fatigue syndrome. Autoimmunity Rev. 2009;8:287–91.

44. Lakhan SE, Kirchgessner A. Gut inflammation in chronic fatigue syndrome. Nutr Metab (Lond). 2010;7(2):79. https://doi.org/10.3389/fnut.2010.00079.

45. Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med. 2000;160:221–7.

46. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome| NINDS Common Data Elements https://www.commondataelements.ninds.nih.gov/MyalgicEncephalomyelitis/ChronicFatigueSyndrome. Accessed 25 May 2020.